Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;15(2):124–132. doi: 10.1111/j.1750-3639.2005.tb00507.x

New Roles for Galectins in Brain Tumors—From Prognostic Markers to Therapeutic Targets

Brianna N Stillman 1, Paul S Mischel 1, Linda G Baum 1,✉
PMCID: PMC8095905  PMID: 15912884

Abstract

Despite advances in diagnosis and treatment, brain tumors continue to be the leading cause of cancer‐related death in patients under 35 years of age, demonstrating the need for better prognostic and therapeutic targets. Galectins, a family of mammalian carbohydrate binding proteins, are involved in many processes important for tumor survival and dissemination, including proliferation, apoptosis, transcriptional regulation, intracellular signaling, cell adhesion, and cell migration. Several galectins are expressed in human brain, with many galectins demonstrating altered expression during tumor progression. Thus, galectins and the functions regulated by this family of proteins are potential targets for the diagnosis and treatment of brain cancer. This review highlights the roles of galectins in cancer and specifically, the developing field of galectins in brain cancer.

Full Text

The Full Text of this article is available as a PDF (192.2 KB).

REFERENCES

  • 1. Ahmad N, Gabius HJ, Andre S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F, Brewer CF (2004) Galectin‐3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross‐linked complexes. J Biol Chem 279:10841–10847. [DOI] [PubMed] [Google Scholar]
  • 2. Ahmad N, Gabius HJ, Sabesan S, Oscarson S, Brewer CF (2004) Thermodynamic binding studies of bivalent oligosaccharides to galectin‐1, galectin‐3, and the carbohydrate recognition domain of galectin‐3. Glycobiology 14:817–825. [DOI] [PubMed] [Google Scholar]
  • 3. Akahani S, Nangia‐Makker P, Inohara H, Kim HR, Raz A (1997) Galectin‐3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl‐2 family. Cancer Res 57:5272–5276. [PubMed] [Google Scholar]
  • 4. Allen HJ, Sharma A, Ahmed H, Piver MS, Gamarra M (1993) Galaptin and galaptin‐binding glycoconjugates in serum and effusions of carcinoma patients. Tumour Biol 14:360–368. [DOI] [PubMed] [Google Scholar]
  • 5. Allione A, Wells V, Forni G, Mallucci L, Novelli F (1998) Beta‐galactoside‐binding protein (beta GBP) alters the cell cycle, up‐regulates expression of the alpha‐ and beta‐chains of the IFN‐gamma receptor, and triggers IFN‐gamma‐mediated apoptosis of activated human T lymphocytes. J Immunol 161:2114–2119. [PubMed] [Google Scholar]
  • 6. Bernerd F, Sarasin A, Magnaldo T (1999) Galectin‐7 overexpression is associated with the apoptotic process in UVB‐induced sunburn keratinocytes. Proc Natl Acad Sci U S A 96:11329–11334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Bladier D, Joubert R, Avellana‐Adalid V, Kemeny JL, Doinel C, Amouroux J, Caron M (1989) Purification and characterization of a galactoside‐binding lectin from human brain. Arch Biochem Biophys 269:433–439. [DOI] [PubMed] [Google Scholar]
  • 8. Bresalier RS, Yan PS, Byrd JC, Lotan R, Raz A (1997) Expression of the endogenous galactose‐binding protein galectin‐3 correlates with the malignant potential of tumors in the central nervous system. Cancer 80:776–787. [PubMed] [Google Scholar]
  • 9. Brewer CF (2004) Thermodynamic binding studies of galectin‐1, ‐3 and ‐7. Glycoconj J 19:459–465. [DOI] [PubMed] [Google Scholar]
  • 10. Brunger AT, Milburn MV, Tong L, de Vos AM, Jancarik J, Yamaizumi Z, Nishimura S, Ohtsuka E, Kim SH (1990) Crystal structure of an active form of RAS protein, a complex of a GTP analog and the HRAS p21 catalytic domain. Proc Natl Acad Sci U S A 87:4849–4853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Califice S, Castronovo V, Bracke M, Van Den Brule F (2004) Dual activities of galectin‐3 in human prostate cancer: tumor suppression of nuclear galectin‐3 vs tumor promotion of cytoplasmic galectin‐3. Oncogene 23:7527–7523. [DOI] [PubMed] [Google Scholar]
  • 12. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R (2001) Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11:12–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ, Kiss R (2002) Galectin‐1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61:585–596. [DOI] [PubMed] [Google Scholar]
  • 14. Caron M, Joubert R, Bladier D (1987) Purification and characterization of a beta‐galactoside‐binding soluble lectin from rat and bovine brain. Biochim Biophys Acta 925:290–296. [DOI] [PubMed] [Google Scholar]
  • 15. Casey MB, Lohse CM, Lloyd RV (2003) Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin‐3, and HBME‐1. Endocr Pathol 14:55–60. [DOI] [PubMed] [Google Scholar]
  • 16. Cooper DN, Barondes SH (1990) Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism. J Cell Biol 110:1681–1691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Cooper DN (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta 1572:209–231. [DOI] [PubMed] [Google Scholar]
  • 18. Cornillot JD, Pontet M, Dupuy C, Chadli A, Caron M, Joubert‐Caron R, Bourin P, Bladier D (1998) Production and characterization of a monoclonal antibody able to discriminate galectin‐1 from galectin‐2 and galectin‐3. Glycobiology 8:425–432. [DOI] [PubMed] [Google Scholar]
  • 19. Debray C, Vereecken P, Belot N, Teillard P, Brion JP, Pandolfo M, Pochet R (2004) Multifaceted role of galectin‐3 on human glioblastoma cell motility. Biochem Biophys Res Commun 325:1393–1398. [DOI] [PubMed] [Google Scholar]
  • 20. Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D, Lotan R (1999) Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin‐1. Int J Oncol 14:225–232. [DOI] [PubMed] [Google Scholar]
  • 21. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ, 3rd (2004) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214–3223. [DOI] [PubMed] [Google Scholar]
  • 22. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S, Raz A (2003) CD29 and CD7 mediate galectin‐3‐induced type II T‐cell apoptosis. Cancer Res 63:8302–8311. [PubMed] [Google Scholar]
  • 23. Gabius HJ, Andre S, Gunsenhauser I, Kaltner H, Kayser G, Kopitz J, Lahm H, Harms D, Szymas J, Kayser K (2002) Association of galectin‐1 ‐ but not galectin‐3‐dependent parameters with proliferation activity in human neuroblastomas and small cell lung carcinomas. Anticancer Res 22:405–410. [PubMed] [Google Scholar]
  • 24. Gillenwater A, Xu XC, El‐Naggar AK, Clayman GL, Lotan R (1996) Expression of galectins in head and neck squamous cell carcinoma. Head Neck 18:422–432. [DOI] [PubMed] [Google Scholar]
  • 25. Gordower L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, Burchert M, Danguy A, Gabius H, Salmon I, Kiss R, Camby I (1999) Galectin‐3 and galectin‐3‐binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol 25:319–330. [DOI] [PubMed] [Google Scholar]
  • 26. Gray CA, Adelson DL, Bazer FW, Burghardt RC, Meeusen EN, Spencer TE (2004) Discovery and characterization of an epithelial‐specific galectin in the endometrium that forms crystals in the trophectoderm. Proc Natl Acad Sci U S A 101:7982–7987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Gu M, Wang W, Song WK, Cooper DN, Kaufman SJ (1994) Selective modulation of the interaction of alpha 7 beta 1 integrin with fibronectin and laminin by L‐14 lectin during skeletal muscle differentiation. J Cell Sci 107 (Pt 1):175–181. [DOI] [PubMed] [Google Scholar]
  • 28. Hadari YR, Arbel‐Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y (2000) Galectin‐8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci 113 (Pt 13):2385–2397. [DOI] [PubMed] [Google Scholar]
  • 29. Hamann KK, Cowles EA, Wang JL, Anderson RL (1991) Expression of carbohydrate binding protein 35 in human fibroblasts: variations in the levels of mRNA, protein, and isoelectric species as a function of replicative competence. Exp Cell Res 196:82–91. [DOI] [PubMed] [Google Scholar]
  • 30. He J, Baum LG (2004) Presentation of galectin‐1 by extracellular matrix triggers T‐cell death. J Biol Chem 279:4705–4712. [DOI] [PubMed] [Google Scholar]
  • 31. Hernandez JD, Baum LG (2002) Ah, sweet mystery of death Galectins and control of cell fate. Glycobiology 12:127R–136R. [DOI] [PubMed] [Google Scholar]
  • 32. Holland EC (2001) Brain tumor animal models: importance and progress. Curr Opin Oncol 13:143–147. [DOI] [PubMed] [Google Scholar]
  • 33. Honjo Y, Nangia‐Makker P, Inohara H, Raz A (2001) Down‐regulation of galectin‐3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7:661–668. [PubMed] [Google Scholar]
  • 34. Horie H, Kadoya T, Hikawa N, Sango K, Inoue H, Takeshita K, Asawa R, Hiroi T, Sato M, Yoshioka T, Ishikawa Y (2004) Oxidized galectin‐1 stimulates macrophages to promote axonal regeneration in peripheral nerves after axotomy. J Neurosci 24:1873–1880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Hoyer KK, Pang M, Gui D, Shintaku IP, Kuwabara I, Liu FT, Said JW, Baum LG, Teitell MA (2004) An anti‐apoptotic role for galectin‐3 in diffuse large B‐cell lymphomas. Am J Pathol 164:893–902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Hughes RC (2001) Galectins as modulators of cell adhesion. Biochimie 83:667–676. [DOI] [PubMed] [Google Scholar]
  • 37. Hynes MA, Gitt M, Barondes SH, Jessell TM, Buck LB (1990) Selective expression of an endogenous lactose‐binding lectin gene in subsets of central and peripheral neurons. J Neurosci 10:1004–1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T (1999) Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475–2484. [PubMed] [Google Scholar]
  • 39. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S (2000) Concentrations of galectin‐3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389–1393. [PubMed] [Google Scholar]
  • 40. Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ (2001) Expression and function of galectin‐3, a beta‐galactoside‐binding protein in activated T lymphocytes. J Leukoc Biol 69:555–564. [PubMed] [Google Scholar]
  • 41. Joubert R, Kuchler S, Zanetta JP, Bladier D, Avellana‐Adalid V, Caron M, Doinel C, Vincendon G (1989) Immunohistochemical localization of a beta‐galactoside‐binding lectin in rat central nervous system. I. Light‐ and electron‐microscopical studies on developing cerebral cortex and corpus callosum. Dev Neurosci 11:397–413. [DOI] [PubMed] [Google Scholar]
  • 42. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T, Hirashima M (2002) Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99:809–816. [DOI] [PubMed] [Google Scholar]
  • 43. Kim HR, Lin HM, Biliran H, Raz A (1999) Cell cycle arrest and inhibition of anoikis by galectin‐3 in human breast epithelial cells. Cancer Res 59:4148–4154. [PubMed] [Google Scholar]
  • 44. Konstantinov KN, Robbins BA, Liu FT (1996) Galectin‐3, a beta‐galactoside‐binding animal lectin, is a marker of anaplastic large‐cell lymphoma. Am J Pathol 148:25–30. [PMC free article] [PubMed] [Google Scholar]
  • 45. Kopitz J, von Reitzenstein C, Burchert M, Cantz M, Gabius HJ (1998) Galectin‐1 is a major receptor for ganglioside GM1, a product of the growth‐controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. J Biol Chem 273:11205–11211. [DOI] [PubMed] [Google Scholar]
  • 46. Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, Cantz M, Gabius HJ (2001) Negative regulation of neuroblastoma cell growth by carbohydrate‐dependent surface binding of galectin‐1 and functional divergence from galectin‐3. J Biol Chem 276:35917–35923. [DOI] [PubMed] [Google Scholar]
  • 47. Kopitz J, Andre S, von Reitzenstein C, Versluis K, Kaltner H, Pieters RJ, Wasano K, Kuwabara I, Liu FT, Cantz M, Heck AJ, Gabius HJ (2003) Homodimeric galectin‐7 (p53‐induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 22:6277–6288. [DOI] [PubMed] [Google Scholar]
  • 48. Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, Graeber S, Herzog V, Pietsch T, Wiestler OD, Probstmeier R (2000) Expression pattern of galectin‐3 in neural tumor cell lines. J Neurosci Res 60:45–57. [DOI] [PubMed] [Google Scholar]
  • 49. Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius HJ (2001) Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT‐PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127:375–386. [DOI] [PubMed] [Google Scholar]
  • 50. Lahm H, Andre S, Hoeflich A, Kaltner H, Siebert HC, Sordat B, von der Lieth CW, Wolf E, Gabius HJ (2004) Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 20:227–238. [DOI] [PubMed] [Google Scholar]
  • 51. Le Marer N, Hughes RC (1996) Effects of the carbohydrate‐binding protein galectin‐3 on the invasiveness of human breast carcinoma cells. J Cell Physiol 168:51–58. [DOI] [PubMed] [Google Scholar]
  • 52. Lee YJ, Song YK, Song JJ, Siervo‐Sassi RR, Kim HR, Li L, Spitz DR, Lokshin A, Kim JH (2003) Reconstitution of galectin‐3 alters glutathione content and potentiates TRAIL‐induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res 288:21–34. [DOI] [PubMed] [Google Scholar]
  • 53. Lipkowitz MS, Leal‐Pinto E, Cohen BE, Abramson RG (2004) Galectin 9 is the sugar‐regulated urate transporter/channel UAT. Glycoconj J 19:491–498. [DOI] [PubMed] [Google Scholar]
  • 54. Lopez‐Lucendo MF, Solis D, Andre S, Hirabayashi J, Kasai K, Kaltner H, Gabius HJ, Romero A (2004) Growth‐regulatory human galectin‐1: crystallographic characterisation of the structural changes induced by single‐site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol 343:957–970. [DOI] [PubMed] [Google Scholar]
  • 55. Lotan R, Belloni PN, Tressler RJ, Lotan D, Xu XC, Nicolson GL (1994) Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. Glycoconj J 11:462–468. [DOI] [PubMed] [Google Scholar]
  • 56. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779–786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, Malorni W, Iacobelli S (2000) Galectin‐3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85:545–554. [PubMed] [Google Scholar]
  • 58. McGraw J, McPhail LT, Oschipok LW, Horie H, Poirier F, Steeves JD, Ramer MS, Tetzlaff W (2004) Galectin‐1 in regenerating motoneurons. Eur J Neurosci 20:2872–2880. [DOI] [PubMed] [Google Scholar]
  • 59. McGraw J, Oschipok LW, Liu J, Hiebert GW, Mak CF, Horie H, Kadoya T, Steeves JD, Ramer MS, Tetzlaff W (2004) Galectin‐1 expression correlates with the regenerative potential of rubrospinal and spinal motoneurons. Neuroscience 128:713–719. [DOI] [PubMed] [Google Scholar]
  • 60. Mischel PS, Cloughesy TF, Nelson SF (2004) DNA‐microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 5:782–792. [DOI] [PubMed] [Google Scholar]
  • 61. Moisan S, Demers M, Mercier J, Magnaldo T, Potworowski EF, St‐Pierre Y (2003) Upregulation of galectin‐7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia 17:751–759. [DOI] [PubMed] [Google Scholar]
  • 62. Moiseeva EP, Spring EL, Baron JH, de Bono DP (1999) Galectin 1 modulates attachment, spreading and migration of cultured vascular smooth muscle cells via interactions with cellular receptors and components of extracellular matrix. J Vasc Res 36:47–58. [DOI] [PubMed] [Google Scholar]
  • 63. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR (2001) Galectin‐3 protects human breast carcinoma cells against nitric oxide‐induced apoptosis: implication of galectin‐3 function during metastasis. Am J Pathol 159:1055–1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Moutsatsos IK, Wade M, Schindler M, Wang JL (1987) Endogenous lectins from cultured cells: nuclear localization of carbohydrate‐binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci U S A 84:6452–6456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Nakajima A, Hida JI, Miyake M, Shindo K, Yasutomi M (1999) Involvement of galectin‐3 expression in colorectal cancer progression and metastasis. Int J Oncol 15:143–148. [DOI] [PubMed] [Google Scholar]
  • 66. Neder LMS, Carlotti CG Jr, Gabbai AA, Rosemberg S, Malheiros SM, Siqueira RPO‐SS, Uno M, Aguiar PH, Miura F, Chammas R, Colli BO, Silva WA Jr ZM (2004) Galectin‐3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol 14:399–405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Outenreath RL, Jones AL (1992) Influence of an endogenous lectin substrate on cultured dorsal root ganglion cells. J Neurocytol 21:788–795. [DOI] [PubMed] [Google Scholar]
  • 68. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ (2001) Association of galectin‐1 and galectin‐3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 29:3595–3602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Paron I, Scaloni A, Pines A, Bachi A, Liu F‐T, Puppin C, Pandolfi M, Ledda L, Di Loreto C, Damante G, Tell G (2003) Nuclear localization of Galectin‐3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 302:545–553. [DOI] [PubMed] [Google Scholar]
  • 70. Paz A, Haklai R, Elad‐Sfadia G, Ballan E, Kloog Y (2001) Galectin‐1 binds oncogenic H‐Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20:7486–7493. [DOI] [PubMed] [Google Scholar]
  • 71. Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G (1998) A novel function for SMN, the spinal muscular atrophy disease gene product, in pre‐mRNA splicing. Cell 95:615–624. [DOI] [PubMed] [Google Scholar]
  • 72. Perillo NL, Pace KE, Seilhamer JJ, Baum LG (1995) Apoptosis of T‐cells mediated by galectin‐1. Nature 378:736–739. [DOI] [PubMed] [Google Scholar]
  • 73. Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG (1997) Galectin‐1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 185:1851–1858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Pesheva P, Kuklinski S, Schmitz B, Probstmeier R (1998) Galectin‐3 promotes neural cell adhesion and neurite growth. J Neurosci Res 54:639–654. [DOI] [PubMed] [Google Scholar]
  • 75. Pesheva P, Urschel S, Frei K, Probstmeier R (1998) Murine microglial cells express functionally active galectin‐3 in vitro. J Neurosci Res 51:49–57. [DOI] [PubMed] [Google Scholar]
  • 76. Pesheva P, Kuklinski S, Biersack HJ, Probstmeier R (2000) Nerve growth factor‐mediated expression of galectin‐3 in mouse dorsal root ganglion neurons. Neurosci Lett 293:37–40. [DOI] [PubMed] [Google Scholar]
  • 77. Probstmeier R, Montag D, Schachner M (1995) Galectin‐3, a beta‐galactoside‐binding animal lectin, binds to neural recognition molecules. J Neurochem 64:2465–2472. [DOI] [PubMed] [Google Scholar]
  • 78. Puche AC, Poirier F, Hair M, Bartlett PF, Key B (1996) Role of galectin‐1 in the developing mouse olfactory system. Dev Biol 179:274–287. [DOI] [PubMed] [Google Scholar]
  • 79. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, Iacobelli S (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response Trends Immunol 23:313–320. [DOI] [PubMed] [Google Scholar]
  • 80. Rabinovich GA, Rubinstein N, Matar P, Rozados V, Gervasoni S, Scharovsky GO (2002) The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin‐1 and Bcl‐2 expression. Cancer Immunol Immunother 50:597–603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Regan LJ, Dodd J, Barondes SH, Jessell TM (1986) Selective expression of endogenous lactose‐binding lectins and lactoseries glycoconjugates in subsets of rat sensory neurons. Proc Natl Acad Sci U S A 83:2248–2252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Reichert F, Saada A, Rotshenker S (1994) Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose‐specific lectin MAC‐2. J Neurosci 14:3231–3245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S, Maurage CA, Kaltner H, Ruchoux MM, Danguy A, Gabius HJ, Salmon I, Kiss R, Camby I (2001) Galectin‐1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33:241–255. [DOI] [PubMed] [Google Scholar]
  • 84. Rossi DL, Acebron A, Santisteban P (1995) Function of the homeo and paired domain proteins TTF‐1 and Pax‐8 in thyroid cell proliferation. J Biol Chem 270:23139–23142. [DOI] [PubMed] [Google Scholar]
  • 85. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin‐1 gene expression in tumor cells results in heightened T‐cell‐mediated rejection; A potential mechanism of tumor‐immune privilege. Cancer Cell 5:241–251. [DOI] [PubMed] [Google Scholar]
  • 86. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, Angeli A, Orlandi F (2001) Galectin‐3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86:5152–5158. [DOI] [PubMed] [Google Scholar]
  • 87. Sango K, Tokashiki A, Ajiki K, Horie M, Kawano H, Watabe K, Horie H, Kadoya T (2004) Synthesis, localization and externalization of galectin‐1 in mature dorsal root ganglion neurons and Schwann cells. Eur J Neurosci 19:55–64. [DOI] [PubMed] [Google Scholar]
  • 88. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A, Campo E (1997) Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113:1906–1915. [DOI] [PubMed] [Google Scholar]
  • 89. Schoeppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an endogenous galactose‐binding lectin correlates with neoplastic progression in the colon. Cancer 75:2818–2826. [DOI] [PubMed] [Google Scholar]
  • 90. Skrincosky DM, Allen HJ, Bernacki RJ (1993) Galaptin‐mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin‐binding glycoproteins. Cancer Res 53:2667–2675. [PubMed] [Google Scholar]
  • 91. Stierstorfer B, Kaltner H, Neumuller C, Sinowatz F, Gabius HJ (2000) Temporal and spatial regulation of expression of two galectins during kidney development of the chicken. Histochem J 32:325–336. [DOI] [PubMed] [Google Scholar]
  • 92. Sturm A, Lensch M, Andre S, Kaltner H, Wiedenmann B, Rosewicz S, Dignass AU, Gabius HJ (2004) Human galectin‐2: novel inducer of T‐cell apoptosis with distinct profile of caspase activation. J Immunol 173:3825–3837. [DOI] [PubMed] [Google Scholar]
  • 93. van den Brule F, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19:537–542. [DOI] [PubMed] [Google Scholar]
  • 94. van den Brule FA, Buicu C, Baldet M, Sobel ME, Cooper DN, Marschal P, Castronovo V (1995) Galectin‐1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209:760–767. [DOI] [PubMed] [Google Scholar]
  • 95. van den Brule FA, Waltregny D, Castronovo V (2001) Increased expression of galectin‐1 in carcinoma‐associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 193:80–87. [DOI] [PubMed] [Google Scholar]
  • 96. Vespa GN, Lewis LA, Kozak KR, Moran M, Nguyen JT, Baum LG, Miceli MC (1999) Galectin‐1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL‐2 production and proliferation. J Immunol 162:799–806. [PubMed] [Google Scholar]
  • 97. Visegrady B, Than NG, Kilar F, Sumegi B, Than GN, Bohn H (2001) Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin‐13). Protein Eng 14:875–880. [DOI] [PubMed] [Google Scholar]
  • 98. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS (1997) Developmental regulation, expression, and apoptotic potential of galectin‐9, a beta‐galactoside binding lectin. J Clin Invest 99:2452–2461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Warfield PR, Makker PN, Raz A, Ochieng J (1997) Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin‐3. Invasion Metastasis 17:101–112. [PubMed] [Google Scholar]
  • 100. Wechsler‐Reya R, Scott MP (2001) The developmental biology of brain tumors. Annu Rev Neurosci 24:385–428. [DOI] [PubMed] [Google Scholar]
  • 101. Wells V, Davies D, Mallucci L (1999) Cell cycle arrest and induction of apoptosis by beta galactoside binding protein (beta GBP) in human mammary cancer cells. A potential new approach to cancer control. Eur J Cancer 35:978–983. [DOI] [PubMed] [Google Scholar]
  • 102. Woo HJ, Shaw LM, Messier JM, Mercurio AM (1990) The major non‐integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac‐2). J Biol Chem 265:7097–7099. [PubMed] [Google Scholar]
  • 103. Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y, Kirino T (2000) Expression of galectin‐1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin‐1 inhibits the growth of 9 glioma cells. J Neurosci Res 59:722–730. [DOI] [PubMed] [Google Scholar]
  • 104. Yang RY, Hsu DK, Liu FT (1996) Expression of galectin‐3 modulates T‐cell growth and apoptosis. Proc Natl Acad Sci U S A 93:6737–6742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Yang RY, Hsu DK, Yu L, Ni J, Liu FT (2001) Cell cycle regulation by galectin‐12, a new member of the galectin superfamily. J Biol Chem 276:20252–20260. [DOI] [PubMed] [Google Scholar]
  • 106. Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, Raz A, Kubo T (2001) Galectin‐3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18:787–792. [DOI] [PubMed] [Google Scholar]
  • 107. Zhou Q, Cummings RD (1993) L‐14 lectin recognition of laminin and its promotion of in vitro cell adhesion. Arch Biochem Biophys 300:6–17. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES